Spermosens (SPERM) Q3 2024 earnings summary

Executive summary

• Achieved key milestones: next-generation male fertility diagnostic product ready for clinical study and first couple recruited for trial.

• Entered agreements for strategic partnerships in the US and Japan, including a memorandum of understanding with a Japanese partner.

• Received approval for a significant clinical study and a broad US patent for JUNO-Checked technology.

• Implemented revised strategy with focus on commercialization, cost reductions, and value creation.

Financial highlights

• Net sales were SEK 0 for both the quarter and nine-month period, unchanged year-over-year.

• Operating loss for Q3 was SEK -2,131k (improved from -2,809k in Q3 2023); nine-month operating loss SEK -6,790k (improved from -9,457k year-over-year).

• Net loss for Q3 was SEK -2,162k (vs. -3,505k Q3 2023); nine-month net loss SEK -7,745k (vs. -10,209k year-over-year).

• Cash and cash equivalents at period end SEK 2,959k (down from SEK 8,639k year-over-year).

• Rights issue in April 2024 raised SEK 24.2 million before costs; further rights issue planned for SEK 22.7 million.

Outlook and guidance

• Interim results from the ongoing clinical study expected by year-end 2024.

• Commercialization strategy focuses on partnerships and licensing in key markets, especially the US and Japan.

• Additional capital required to fund operations over the next 12 months; rights issue planned.